The Stanford University School of Medicine and SanBio, a San Francisco biotechnology company focused on the discovery and development of regenerative cell therapy products, have initiated a phase 1/2a clinical trial testing the safety and efficacy of an allogeneic cell therapy product, SB623, on patients suffering from stable deficits resulting from previous stroke injuries.
"SB623 represents a significant step forward in the development of regenerative therapies for the treatment of brain injury," said Keita Mori, SanBio CEO. "We are pleased to initiate a first-in-man study of SB623."
SB623 will be administered by intracranial injection into the damaged region of the brains of patients who have suffered an ischemic stroke. Product safety is the primary focus of the study but various measurements of efficacy will also be tested.